Last updated: February 19, 2026
Patent DK2736887, titled "SUBSTITUTED 2,3-DIHYDROPYRIDINES AND USES THEREOF," claims a class of chemical compounds and their therapeutic applications. The patent, filed by Lundbeckfond Innovation A/S, addresses the treatment of central nervous system (CNS) disorders.
What Compounds Are Covered by DK2736887?
The core of DK2736887 lies in its definition of a specific chemical structure and its derivatives. The patent claims a compound of Formula I:
R1
|
R2--C----N
| / \
C----C----C
/ \ / \ / \
R3 C R4 C R5
/ \
R6 R7
Where R1 through R7 represent specific substituents as defined in the patent document. These substituents include various organic groups, such as alkyl, aryl, heteroaryl, and alkoxy groups, and can further be substituted. The claims broadly encompass enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of these compounds.
Specifically, the patent claims cover:
- Formula I Compounds: A compound of Formula I, or a pharmaceutically acceptable salt thereof.
- Specific Examples: The patent lists specific examples of compounds falling within Formula I, detailing their chemical names and, in some cases, their synthesis. These examples serve to illustrate the scope of the claimed genus.
- Pharmaceutical Compositions: The patent also claims pharmaceutical compositions containing a compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient.
The detailed definition of the chemical structure and its potential variations is critical for determining the exact scope of protection afforded by the patent.
What Therapeutic Uses Are Claimed?
DK2736887 claims the use of the aforementioned compounds for the treatment of specific medical conditions. The primary focus is on disorders of the central nervous system.
The claimed therapeutic uses include:
- Treatment of CNS Disorders: The patent claims methods of treating a disorder of the central nervous system by administering an effective amount of a compound of Formula I.
- Specific CNS Disorders: While the patent broadly refers to CNS disorders, it often implies or specifies conditions related to neurotransmitter modulation or receptor activity. Further analysis of the patent's detailed description would identify specific target diseases.
- Inhibition of Enzymes or Modulation of Receptors: The underlying mechanism of action often involves the inhibition of specific enzymes or the modulation of receptors within the CNS. The patent details the biological targets and mechanisms by which the claimed compounds exert their therapeutic effects.
The therapeutic claims are directly tied to the pharmacological activity demonstrated by the compounds described.
What Are the Key Claims in DK2736887?
The patent's claims define the legal boundaries of its protection. For DK2736887, the claims are structured to cover the chemical entities and their therapeutic applications.
Key claims include:
- Claim 1: This claim typically defines the core chemical genus. For DK2736887, it is likely the claim covering compounds of Formula I.
- Dependent Claims: Subsequent claims (e.g., Claims 2-10) refine Claim 1 by adding specific limitations or by claiming particular embodiments of the invention. These may specify particular ranges for substituents (R1-R7) or claim specific compounds that are exemplars of Formula I.
- Pharmaceutical Composition Claims: Claims dedicated to pharmaceutical formulations containing the active compounds.
- Method of Treatment Claims: Claims outlining the therapeutic uses of the compounds, often specifying the condition to be treated and the dosage regimen.
The precise wording of each claim dictates the scope of novelty and inventiveness. Analyzing these claims involves understanding chemical nomenclature, structural variations, and the nuances of pharmaceutical claim drafting.
What is the Patent Landscape for DK2736887?
The patent landscape surrounding DK2736887 is shaped by existing intellectual property in the field of CNS therapeutics and related chemical structures. Understanding this landscape is crucial for assessing potential freedom-to-operate issues and identifying competitive innovation.
Key aspects of the landscape include:
- Prior Art: Existing patents and scientific literature that predate the filing of DK2736887 are critical. These prior art documents can limit the scope of the claims or even invalidate the patent if they disclose anticipatory or obvious inventions.
- Competitor Patents: Other companies and research institutions actively patenting compounds and therapies for CNS disorders. These patents may cover similar chemical scaffolds, biological targets, or treatment approaches.
- Patent Filings by Lundbeckfond Innovation A/S: Lundbeckfond Innovation A/S itself has a portfolio of patents related to CNS drugs. Understanding their broader patent strategy provides context for DK2736887.
- Generic Competition: Once patents expire, generic manufacturers can enter the market. The duration of patent protection for DK2736887, including any extensions, is a factor in this regard.
- Freedom-to-Operate (FTO) Analysis: Competitors seeking to develop similar compounds or therapies must conduct FTO analyses to ensure their activities do not infringe on existing patents, including DK2736887.
A comprehensive landscape analysis involves searching patent databases (e.g., Espacenet, USPTO, WIPO) for patents citing DK2736887, patents with similar classifications, and patents filed by key competitors in the CNS therapeutic area.
What are the Implications for R&D and Investment?
The scope and claims of DK2736887 have direct implications for research and development strategies and investment decisions in the pharmaceutical sector.
For R&D:
- Target Identification: The patent guides researchers towards specific chemical spaces and therapeutic targets relevant to CNS disorders.
- Lead Optimization: Understanding the claimed structures can inform medicinal chemistry efforts to discover novel compounds with improved efficacy, safety, or pharmacokinetic profiles.
- Freedom-to-Operate: Companies developing new CNS therapies must carefully navigate the claims of DK2736887 to avoid infringement. This may involve designing around the patent or seeking licenses.
For Investment:
- Pipeline Analysis: Investors assess the strength and breadth of a company's patent portfolio, such as that surrounding DK2736887, as an indicator of future market exclusivity and potential revenue.
- Competitive Advantage: Patents provide a period of market exclusivity, allowing patent holders to recoup R&D costs and generate profits. The claims of DK2736887 define the duration and scope of this advantage.
- Valuation: The intellectual property position, including granted patents like DK2736887, is a significant factor in the valuation of pharmaceutical companies and their drug candidates.
- Risk Assessment: Investors evaluate the risk of patent challenges, invalidation, or infringement lawsuits, which can impact the commercial viability of a drug.
The lifecycle of DK2736887, from its filing date through its expiration, will influence market dynamics for CNS treatments.
Key Takeaways
- Patent DK2736887 protects a class of substituted 2,3-dihydropyridine compounds and their use in treating central nervous system disorders.
- The patent's claims define specific chemical structures and therapeutic applications, establishing the boundaries of intellectual property protection.
- The patent landscape includes prior art, competitor activities, and Lundbeckfond Innovation A/S's broader patent portfolio in the CNS therapeutic area.
- DK2736887 impacts R&D by guiding chemical space exploration and influences investment decisions by defining market exclusivity and competitive advantage.
Frequently Asked Questions
-
What is the priority date of DK2736887?
The priority date is critical for determining the prior art that can be used to challenge the patent's validity. This date is typically established by reference to an earlier filed application, often a PCT or a national application in another jurisdiction. Identifying this date requires consulting the patent document's filing history.
-
When does DK2736887 expire?
The expiry date of a European patent is generally 20 years from the filing date, subject to the payment of annual renewal fees. For Danish national patents, the term is also 20 years from the filing date. Specific details regarding renewal fees and any potential extensions (e.g., for pediatric exclusivity or SPCs) would need to be verified through official patent registers.
-
Are there any granted SPCs related to DK2736887?
A Supplementary Protection Certificate (SPC) can extend patent protection for a medicinal product to compensate for the time lost during the regulatory approval process. Whether SPCs have been sought or granted for products covered by DK2736887 would require searching SPC databases maintained by national patent offices or the EUIPO.
-
What is the classification of DK2736887 in patent databases?
Patent classification systems, such as the International Patent Classification (IPC) or Cooperative Patent Classification (CPC), categorize inventions. DK2736887 would be assigned codes related to organic chemistry (e.g., C07D for heterocyclic compounds) and medicinal preparations (e.g., A61K for preparations for medical, dental, or hygienic purposes).
-
Can a company develop a generic version of a drug claimed in DK2736887 before its expiry?
Developing and marketing a generic version of a drug that is covered by an unexpired patent constitutes patent infringement. Companies typically wait until the patent expires, or they obtain a license from the patent holder, to launch a generic product. Furthermore, even after patent expiry, regulatory exclusivity periods may still apply.
Citations
[1] Lundbeckfond Innovation A/S. (Undated). SUBSTITUTED 2,3-DIHYDROPYRIDINES AND USES THEREOF. DK2736887. Danish Patent Office.
